Orion PharmaDHA:ORIONPHARM 71 Net Current Asset Value is BDT-83.98 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.26 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 104 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 961537.5% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Orion Pharma's net current asset value per share for the quarter that ended in Mar. 2026 was BDT-83.98.
The historical rank and industry rank for Orion Pharma's Net Current Asset Value or its related term are showing as below:
DHA:ORIONPHARM's Price-to-Net-Current-Asset-Value is not ranked *
in the Utilities - Independent Power Producers industry.
Industry Median: 5.175 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Orion Pharma (DHA:ORIONPHARM) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Orion Pharma Net Current Asset Value Related Terms
Orion Pharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Net Current Asset Value Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Price-to-Net-Current-Asset-Value vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of BDT-83.98 mean?
Orion Pharma (DHA:ORIONPHARM) has a Net Current Asset Value of BDT-83.98 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #999999 out of 104 companies in the Utilities - Independent Power Producers industry.
Is Orion Pharma's Net Current Asset Value too high?
Orion Pharma's current Net Current Asset Value is BDT-83.98. Based on the distribution chart, Orion Pharma ranks #999999 out of 104 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Net Current Asset Value compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #999999 out of 104 companies for Net Current Asset Value. This places Orion Pharma in the lower half of its industry. The industry median Net Current Asset Value is 5.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for an Utilities - Independent Power Producers company?
The median Net Current Asset Value among Utilities - Independent Power Producers companies is 5.18, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Net Current Asset Value is 5.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Net Current Asset Value is BDT-83.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.26, compared to a current price of BDT28.30 — trading 39.7% above its estimated fair value. The current Net Current Asset Value is BDT-83.98. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Net Current Asset Value is BDT-83.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.30 is trading 39.7% above its estimated GF Value™ of BDT20.26.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Net Current Asset Value: BDT-83.98
GF Value™: BDT20.26 vs. price of BDT28.30 (39.7% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
